Valrubicin

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Valrubicin is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1998. DrugCentral lists 1 molecular target, including TOP2A. Recorded indications include Malignant tumor of urinary bladder.

• Approval status: ofp (first approved 1998 by the FDA).
• Molecular targets: TOP2A (1 listed in DrugCentral).
• Indications: Malignant tumor of urinary bladder.
• ATC code: L01DB09 (Anthracyclines and related substances).
• Molecular formula: C34H36F3NO13; molecular weight 723.65 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Malignant tumor of urinary bladder

Contraindications (7)

• Bladder muscle dysfunction - overactive
• Bladder Surgery
• Breastfeeding (mother)
• Pregnancy, function
• Rupture of bladder
• Small Capacity Bladder
• Urinary tract infectious disease

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
DNA topoisomerase 2-alpha	TOP2A	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1998-09-25	FDA	—	ENDO PHARM	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01DB09	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES › Anthracyclines and related substances

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Bladder instillation procedure	194.0
Urge incontinence	119.4
Underdose	67.4
Bladder spasm	61.7

Chemical structure

• Molecular formula: C₃₄H₃₆F₃NO₁₃
• Molecular weight: 723.65 g/mol
• CAS number: 56124-62-0
• InChIKey: ZOCKGBMQLCSHFP-KQRAQHLDSA-N
• PubChem CID: 454216

CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C2=C(C1)C(O)=C1C(=O)C3=CC=CC(OC)=C3C(=O)C1=C2O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Valrubicin used for?

DrugCentral lists the following indications for Valrubicin: Malignant tumor of urinary bladder.

How does Valrubicin work?

Its molecular targets in DrugCentral include TOP2A (inhibitor).

When was Valrubicin first approved?

Valrubicin was first approved by the FDA in 1998.

What is the chemical formula of Valrubicin?

Valrubicin has the molecular formula C34H36F3NO13 and a molecular weight of 723.65 g/mol.

Sources

• DrugCentral drug card 2805 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1096885 — compound record and bioactivity
• PubChem CID 454216 — chemical identifiers
• DrugBank DB00385 — drug record
• FDA UNII 2C6NUM6878 — substance identity
• DailyMed: FDA labels for Valrubicin — current prescribing information (label search)
• UniProt P11388 (TOP2A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.